宫腔内输注少白细胞富血小板血浆是复发性植入失败患者的一种有效治疗方案：一项回顾性队列研究。
Intrauterine Infusion of Leukocyte-Poor Platelet-Rich Plasma Is an Effective Therapeutic Protocol for Patients with Recurrent Implantation Failure: A Retrospective Cohort Study.
作者信息
Ban Yanna, Yang Xiaoliang, Xing Yan, Que Wenjun, Yu Zebo, Gui Wenwu, Chen Ying, Liu Xiru
机构信息
Reproductive Medicine Center, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China.
Department of Blood Transfusion, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuzhong District, Chongqing 400016, China.
出版信息
J Clin Med. 2023 Apr 12;12(8):2823. doi: 10.3390/jcm12082823.
BACKGROUND
The clinical application of autologous leukocyte-poor platelet-rich plasma (LP-PRP) in patients with recurrent implantation failure (RIF) is rare. This retrospective observational cohort study aimed to evaluate the efficacy of LP-PRP intrauterine infusion in patients with RIF.
METHODS
Patients with RIF undergoing frozen embryo transfer (FET) from January 2019 to December 2021 ( = 118) were enrolled, with those undergoing LP-PRP intrauterine infusion as the PRP group ( = 64), and those receiving no LP-PRP treatment as the control group ( = 54). The beta-human chorionic gonadotropin (β-hCG)-positive rate, clinical pregnancy rate (CPR), live birth rate (LBR), and miscarriage rate (MR) per ET cycle were compared.
RESULTS
The β-hCG-positive rate (57.8% vs. 38.9%, = 0.041), CPR (45.3% vs. 24.5%, = 0.022), and LBR per ET cycle (42.2% vs. 18.5%, = 0.009) were higher in the PRP group than in the control group, and the three variables (62.5% vs. 41.2%, = 0.040, 47.5% vs. 23.5%, = 0.033, and 47.5% vs. 20.6%, = 0.027) in the PRP group transferred with the were also higher than those in the control group. The MR was similar in all groups.
CONCLUSIONS
The LP-PRP treatment could improve the β-hCG-positive rate, CPR, and LBR in RIF patients undergoing FET cycles.
背景
自体少白细胞富血小板血浆（LP-PRP）在反复种植失败（RIF）患者中的临床应用较少。这项回顾性观察队列研究旨在评估LP-PRP宫腔内输注对RIF患者的疗效。
方法
纳入2019年1月至2021年12月期间接受冻融胚胎移植（FET）的RIF患者（n = 118），其中接受LP-PRP宫腔内输注的患者作为PRP组（n = 64），未接受LP-PRP治疗的患者作为对照组（n = 54）。比较每个ET周期的β-人绒毛膜促性腺激素（β-hCG）阳性率、临床妊娠率（CPR）、活产率（LBR）和流产率（MR）。
结果
PRP组每个ET周期的β-hCG阳性率（57.8%对38.9%，P = 0.041）、CPR（45.3%对24.5%，P = 0.022）和LBR（42.2%对18.5%，P = 0.009）均高于对照组，并且移植优质胚胎的PRP组的这三个变量（62.5%对41.2%，P = 0.040；47.5%对23.5%，P = 0.033；47.5%对20.6%，P = 0.027）也高于对照组。所有组的MR相似。
结论
LP-PRP治疗可提高接受FET周期的RIF患者的β-hCG阳性率、CPR和LBR。
Zotero 插件